Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 2/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372501 | 0.81 | GRIA2 (0.64) | GRIA2GRIA4PDE10APIP4K2ACYP2C9 | |
| SCHEMBL13863355 | 0.80 | GRIA2 (0.55) | GRIA2GRIA4PDE10APIP4K2ACYP2C9 | |
| SCHEMBL8287626 | 0.79 | GRIA2 (0.43) | GRIA2GRIA4PDE10APIP4K2A | |
| SCHEMBL4370965 | 0.68 | GRIA2 (0.49) | GRIA2GRIA4CYP2C9LMNA | |
| SCHEMBL11562716 | 0.67 | KLK1 (0.51) | LMNA | |
| SCHEMBL4374436 | 0.66 | GRIA2 (0.47) | GRIA2GRIA4PDE10APIP4K2A | |
| SCHEMBL8288458 | 0.65 | GRIA2 (0.65) | GRIA2GRIA4PDE10APIP4K2A | |
| SCHEMBL4384179 | 0.65 | GRIA4 (0.57) | GRIA2GRIA4 | |
| SCHEMBL10371010 | 0.64 | ALDH1A1 (0.38) | CYP2C9LMNA | |
| SCHEMBL10375537 | 0.64 | ALDH1A1 (0.36) | CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | GRIA2 17/4885GRIA4 16/4885PDE10A 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.